Prothena Corporation plc PRTA
8.56 USD -0.21 (-2.45%)
At closeNov 10, 2026, 4:01 PM EST
8.56 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
8.32 Day range 8.76
7.73 52-week range 11.80
- YTD
- -10.37%
- 1 year
- -18.71%
News
zacks.com Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High? The consensus price target hints at a 120.2% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
defenseworld.net Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00 Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat.com…
businesswire.com Prothena Reports Third Quarter 2026 Financial Results and Business Highlights DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.
defenseworld.net Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares of Company Stock Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully acquired 50,000 shares of the company's stock in a transaction on Friday, October 23rd. The shares were…
defenseworld.net Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Stock Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 100,000 shares of the business's stock in a transaction that occurred on Thursday, October 22nd.…
defenseworld.net Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average – What’s Next? Prothena Corporation plc (NASDAQ: PRTA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.26 and traded…
zacks.com Prothena's Partnership Strategy: Growth Driver or Limitation? PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.
defenseworld.net Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57 Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat.com…
defenseworld.net Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 125,000 Shares Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 125,000 shares of the business's stock in a transaction on Wednesday, October 7th. The stock was…
zacks.com CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better…
zacks.com 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
defenseworld.net Prothena Corporation plc (NASDAQ:PRTA) Receives $24.57 Consensus PT from Analysts Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm,…
businesswire.com Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
zacks.com KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for…
zacks.com PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
benzinga.com CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of…
zacks.com Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.
businesswire.com Prothena Reports Second Quarter 2026 Financial Results and Business Highlights DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.
defenseworld.net Prothena (NASDAQ:PRTA) Share Price Passes Below 200-Day Moving Average – Time to Sell? Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $9.46 and traded as…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI,…
zacks.com PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
zacks.com SRPT or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value…
benzinga.com UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20 Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $19 to $20.
benzinga.com Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $(0.34) by 276.47 percent. This is a 153.57 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter…
benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $12 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $11 to $12.
benzinga.com Prothena Corp Q4 Earnings Assessment 
benzinga.com Prothena Corp Q4 EPS $(0.40) Beats $(0.54) Estimate, Sales $21.000K Miss $1.334M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 62.96 percent increase over losses of…
benzinga.com Earnings Scheduled For February 19, 2026 
benzinga.com Exploring Prothena Corp's Earnings Expectations 
benzinga.com Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19 Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $11 to $19.
benzinga.com Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a…
benzinga.com Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.- benzinga.com Prothena Presents Phase 2 Clinical Study Data For Coramitug For Treatment Of ATTR Amyloidosis With Cardiomyopathy American Heart Association's Circulation Journal Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the…
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $30 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $20 to $30.
- benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
benzinga.com Prothena Corp Q3 Adj. EPS $(0.68) Beats $(0.69) Estimate, Sales $2.415M Miss $6.639M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.69) by 1.02 percent. This is a 38.18 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $36 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and raises the price target from $15 to $36.
- benzinga.com Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $20 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $14 to $20.
- benzinga.com Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation…
benzinga.com Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $11 JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $29 to $11.
benzinga.com FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
benzinga.com Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.